Exhibit (c)(6)

Board of Directors of Shakespeare Presentation to the Special Committee October 26, 2010 Confidential Presentation

Table of Contents Introduction Positioning and Assessment of Shakespeare Preliminary Valuation Analysis Issues Before the Special Committee ________________________________________________________________________________________ Appendices Leveraged Finance Ownership Profile Special Committee Decision Framework and Go-Shop Overview Comparable Companies

Introduction

Dedicated Project Team Laurence Braham Managing Director Head of Global Electronics (Menlo Park) Senior Sponsorship Global Technology Global Mergers & Acquisitions Richard Hardegree Managing Director Head of Global Electronics M&A (Menlo Park) Marvin Larbi-Yeboa Vice President (Menlo Park) Global Finance Jean-Francois Astier Managing Director Head of Leveraged Finance, Americas (New York) Barclays Capital will bring the most experienced team to this important transaction Brano Perkovich Vice President (Menlo Park) Mike Parker Associate (Menlo Park) Jason Cha Associate (New York) Evan Scibetta Associate (Menlo Park) Shakespeare Laurence Goldberg Managing Director Head of Global Technology Group (New York) Stu Francis Vice Chairman Chairman of Global Technology Group (Menlo Park) Aaron Cheng Analyst (Menlo Park) 1

Team Background Laurence Braham Managing Director Global Head of Electronics 19 years of experience in finance and investment banking Joined Barclays Capital in 2006 Earned M.A. from Oxford University Directly participated in 100+ completed M&A transactions, IPOs, and equity and debt transactions Relevant transactions include Applied Films / AMAT, ASMI / AMAT, Avago, Blackstone / Freescale, Eagle Test / Teradyne, KLA Tencor / ICOS Vision, Mykrolis / Entegris, NPTest / Credence, NXP IPO, Sensata IPO, Shakespeare IPO and Follow On, Veeco / FEI, Wintegra / PMC Sierra Stu Francis Vice Chairman Chairman of Global Technology 32 years of experience in finance and investment banking Joined Barclays Capital in 1991 Earned B.A. from Princeton University and MBA from Stanford Graduate School of Business Directly participated in over 500 transactions Relevant transactions include those involving Amgen, Aruba, Applied Materials, Cisco Systems, eBay, Google, Intel, LSI Logic, Qualcomm, RIMM, Seagate Technology, SunPower, Symantec, Yahoo Richard Hardegree Managing Director Global Head of Electronics M&A 17 years of experience in finance and investment banking Joined Barclays Capital in 2006 Earned A.B. from Dartmouth College and J.D. from Columbia Law School Directly participated in 100+ completed M&A transactions Selected Special Committee Representation: ASE Test, Ikanos, Avant!, NPTest, Vons Relevant transactions include 2Wire / Pace, Applied Films / AMAT, AMD / Mubadala joint venture, AMD DTV Business, Avago Storage Semi Business, Cisco / Starent, Eagle Test / Teradyne, KLA Tencor / ICOS Vision, NSN / Motorola, Wintegra / PMC Sierra Marvin Larbi-Yeboa Vice President Global M&A 5 years of experience in finance and investment banking Joined Barclays Capital in 2005 Earned B.S. from Georgia Institute of Technology and MBA from Stanford Graduate School of Business Directly participated in 19+ completed M&A transactions Relevant transactions include 2Wire / Pace, AMD / Mubadala joint venture, ASE / ASE Test, ATIC / Chartered, Blackstone / Freescale, Cisco / Starent, Cypress / SunPower spin-off, KLA Tencor / ICOS Vision, Wintegra / PMC Sierra ___________________________ Note: All four joined Lehman Brothers prior to Barclays Capital's acquisition. 2

Leading Special Committee advisor Advised on over 85 Special Committee assignments valued at over $150 billion Rigorous internal fairness opinion review process Unimpeached record as a Special Committee advisor Barclays Capital is free of any actual or perceived conflict of interest Leading M&A advisor with #3 ranking in U.S. and #1 ranking in Technology in 2010 Top advisor in sponsor related transactions Deep advisory and special committee experience including many high profile and electronics transactions Outstanding electronics industry and enterprise knowledge and expertise Intimate knowledge of the trends, companies and individuals that drive the industry Very familiar with Shakespeare and parties involved Thorough understanding of potential alternatives available to Shakespeare Advised on many of the largest and most relevant technology and go private transactions Ability to evaluate and negotiate any relevant leveraged finance terms Leading provider of high yield, leveraged loan and securitized financing for LBOs and Recapitalizations Involved in 75% of the recent significant LBOs Unique, dedicated equity capital markets and risk arbitrage team available to provide insight on investor sentiment Why Barclays Capital? Barclays Capital is uniquely qualified to advise the Special Committee Leading Special Committee Expertise ? Committed and Experienced M&A Transaction Execution Team ? Highly Relevant Industry Knowledge ? ? Unique Debt & Equity Market Expertise and Perspectives ? Independent 3

Financial Advisor $13.7 billion transaction value have contributed pipeline and midstream assets to February 2010 Financial Advisor $5.8 billion transaction value has acquired July 2010 Barclays Capital: A Trusted M&A Advisor Financial Advisor $41.0 billion transaction value has been acquired by June 2010 Exclusive M&A Advisor $5.8 billion transaction value has agreed to sell its stake in Pending Financial Advisor $8.6 billion transaction value has divested access lines to July 2010 Exclusive Financial Advisor €6.6 billion transaction value has acquired the pharmaceutical division of February 2010 Financial Advisor $22.4 billion transaction value has acquired February 2010 Special Advisor to MetLife Board $15.5 billion transaction value has agreed to acquire Pending Financial Advisor $9.0 billion transaction value Pending Financial Advisor $22.3 billion transaction value has agreed to acquire Pending ___________________________ Source: Dealogic. Reflects data YTD through 10/25/2010. Note: Rankings represent M&A completed and any involvement. Sole Financial Advisor $42.5 billion transaction value has agreed to acquire oil- drilling rights from Pending have agreed to acquire Lead Financial Advisor and Lead Financing Coordinator $2.4 billion transaction value Pending has agreed to acquire Financial Advisor $43.4 billion transaction value Pending Government of Brazil 2010 YTD M&A Rankings Global M&A Americas M&A Rank Bank Value ($B) 1 Goldman Sachs $291 2 JP Morgan 256 3 Morgan Stanley 246 4 Barclays Capital 244 5 Citi 240 6 Credit Suisse 217 7 Bank of America Merrill 210 8 UBS 190 9 Deustche Bank 168 10 Rothschild 168 Rank Bank Value ($B) 1 Barclays Capital $201 2 Goldman Sachs 193 3 JP Morgan 167 4 Citi 164 5 Morgan Stanley 154 6 Credit Suisse 146 7 Deutsche Bank 118 8 Bank of America Merrill 118 9 UBS 87 10 Lazard 72 disposal of UK regulated and non- regulated network activities to has agreed to merge with Lead Financial Advisor $17.5 billion transaction value Pending 4

The Barclays Capital team has played a leading role in related party transactions that required a Special Committee, having executed over 85 related party transactions with a total value of ~$164 billion Barclays Capital Has Extensive Experience in Advising Special Committees Sellside Financial Advisor has been acquired by Jul-07 Sellside Financial Advisor Sale of 100% of outstanding shares to Jul-07 Buyside Financial Advisor has acquired Feb-07 Sellside Financial Advisor Sale of outstanding publicly held shares of NetRatings to VNU Jun-07 Sellside Financial Advisor Nov-05 has been privatized by Sellside Financial Advisor Oct-05 has been privatized by Financial Advisor has merged with Jul-04 Sellside Financial Advisor has been acquired by an Investor Group Sept-05 Sellside Financial Advisor has been acquired by Jul-05 Sellside Financial Advisor has been acquired by May-05 Buyside Financial Advisor has acquired Dec-04 Financial Advisor has merged with CNL Hospitality Properties CNL Hospitality Corp. Jul-04 Financial Advisor Apr-04 has agreed to a recombination of its PCS shares into FON shares Financial Advisor Nov-03 has agreed to the reclassification of its dual-class equity structure to a single voting class of stock Buyside Financial Advisor Mar-03 has acquired the outstanding publicly held minority interest in Sellside Financial Advisor has been acquired by Sept-07 Sellside Financial Advisor has been acquired by Oct-08 Sellside Financial Advisor ASE Test has been privatized by Advanced Semiconductor Engineering, Inc. May-08 Sellside Financial Advisor has withdrawn it's bid for 100% of The Dolan Family Oct-07 Sole Bookrunner has issued secondary shares to management Sept-09 Special Committee Advisor has agreed to acquire Nov-09 HanseNet Telekommunikation from Telecom Italia Special Committee Advisor has agreed to acquire Dec-09 BPW Acquisition Corp. Financial Advisor July-10 has acquired Special Committee Advisor has acquired Feb-10 5

Dominant Technology Franchise ___________________________ Source: Thomson Financial. Data as of 10/25/10. League table includes enterprise values on announced and non-cancelled transactions for targets over $100 million only. Source: Bloomberg. Data as of 9/20/10. Represents total volume. Source: Dealogic. Data as of 10/1/10. Includes all technology equity and equity-linked transactions by U.S. issuers greater than $25mm. Represents total volume. 2010 YTD Global Tech M&A (1) has agreed to acquire $5.8 billion transaction value Financial Advisor July 2010 has agreed to acquire $1.3 billion transaction value Financial Advisor August 2010 (Identity & Authentication Business) $1.2 billion transaction value Exclusive Financial Advisor Pending has agreed to acquire certain assets of 2010 YTD U.S. Tech Fixed Income (2) $3.0 billion FRNs due 2012 1.250% Notes due 2013 2.125% Notes due 2015 $4.75 billion 0.875% Notes due 2013 1.625% Notes due 2015 3.000% Notes due 2020 4.500% Notes due 2040 Joint Bookrunner September 2010 Joint Bookrunner September 2010 $1.5 billion 1.400% Notes due 2013 2.300% Notes due 2015 5.400% Notes due 2040 Joint Bookrunner September 2010 $500 million 6-year Senior Notes $250 million 3-year Senior Notes Barclays Capital has established a leadership position in all 3 major product categories Bank Value ($BN) Barclays Capital $25.4 Morgan Stanley $25.3 Goldman Sachs $22.5 JP Morgan $16.7 Deutsche Bank $16.6 Bank Volume ($BN) JP Morgan $15.3 Barclays Capital $12.3 Citi $9.3 Goldman Sachs $8.9 Wells Fargo $7.0 Joint Bookrunner July 2010 Acquisition of Broadband Wireless Spectrum in India $1.1 billion transaction value Exclusive Financial Advisor Pending 2010 YTD U.S. Tech Equity Issuance (3) $100 million Initial Public Offering Pending Joint Bookrunner $476 million Initial Public Offering August 2010 Joint Bookrunner $654 million Initial Public Offering March 2010 Joint Bookrunner $745 million Initial Public Offering $501 million | $304 million Follow-on Offerings Aug 2010 | Jan 2010 | Aug 2009 Joint Bookrunner Bank Volume ($BN) Morgan Stanley $7.1 Goldman Sachs $4.8 Barclays Capital $4.5 Deutsche Bank $4.2 JP Morgan $4.1 6

Extensive Knowledge of the Leveraged Finance Markets Barclays Capital's advisory expertise is complemented by a leading Leveraged Finance practice with extensive knowledge of market terms and evaluating financing proposals (involvement in 75% of the past significant LBOs) LBOs to Date Since the Return of the Credit Markets Target Buyer Size BarCap Involvement NBTY Carlyle $3.8bn Vertafore TPG $1.4bn Inventiv Health Thomas H. Lee $1.2bn Interactive Data Silver Lake / Warburg $3.4bn Iowa Telecom Windstream $5.6bn CKE Restaurants Apollo $1.0bn Sophos Apax $0.9bn Dyn Corp Cerberus $1.5bn Detroit MC Vanguard $2.2bn American Tire TPG $1.3bn Sonic Wall Thoma Bravo $0.7bn Michael Foods GS Capital Partners $1.8bn Transunion Madison Dearborn $1.6bn Protection One GTCR $0.8bn BWAY Holding Madison Dearborn $0.9bn RCN ABRY Partners $1.2bn Sedgwick CMS Stone Point / H&F $1.1bn SkillSoft Berkshire / Bain / Advent $1.1bn Styron Bain Capital $1.6bn Target Buyer Size BarCap Involvement Dave And Busters Oak Hill $0.6bn Hillman Companies Oak Hill $0.8bn Tommy Hilfiger PVH $3.1bn Kettle Foods Diamond Foods $0.6bn P&G Pharma Warner Chilcott $3.1bn Infogroup CCMP $0.6bn TASC Advisory GA / KKR $1.7bn Birds Eye Pinnacle (BX) $1.3bn Busch Ent. Blackstone $2.4bn Datatel H&F / JMI $0.6bn Johnson Diversey CD&R $2.6bn Skype SLP / eBay Consortium $3.0bn IMS Health TPG / CPP $5.2bn 7

Barclays Capital's Relationship with Shakespeare September 2009 $6 million/$33 million Block Trades March 2005 $125 million Senior Secured Notes Shakespeare January 2007 $175 million Follow-on Offering Shakespeare February 2006 $164 million Initial Public Offering Shakespeare Shakespeare / April 2010 $46 million Block Trade Shakespeare / April 2008 $9 million Block Trade Shakespeare / Barclays Capital has a deep understanding of Shakespeare having been one of a few banks to work with the Company on a variety of financing transactions ___________________________ Note: Barclays Capital transactions before September 2008 were executed by Lehman Brothers prior to Barclays Capital's acquisition. 8

Positioning and Assessment of Shakespeare

Summary Assessment of Shakespeare Shakespeare is demonstrating strong execution in its business strategy Continued leadership in specialty DRAM modules Developed incumbency in high growth DRAM market in Brazil Established leading SSD market position across embedded and defense applications Positioned to capitalize on large Enterprise SSD market opportunity Impressive financial model - profitability and cash flow momentum Although a complex investment thesis for investors to digest 84% of revenues derived from DRAM today Corporate gross margins in mid 20's Brazil market not well followed by investors Complex business mix Businesses exhibit different growth rates Higher margin SSD exposure likely to be offset by lower margin Flash growth in Brazil Investors waiting for new investments to pan out Translates into a discounted market multiple for the company vs. its expected growth rates No clear public benchmarks for the business DRAM revenue scale a likely overhang for Shakespeare's valuation multiple High potential valuation businesses, such as enterprise SSD, likely to be undervalued within Shakespeare given relative scale and lack of financial clarity 9

Addresses both large and stable specialized DRAM market, as well as high growth emerging markets Shakespeare Has Successfully Diversified Its Business Growth Initiatives High mix/low volume portfolio of 4,000+ highly customizable products Specialized DRAM focuses on stable, attractive markets Leading edge, specialty products driving solid margins Focus on growing networking, telecom and industrial markets Successful logistics business leveraging Shakespeare's extensive DRAM knowledge and expertise Unique module test offerings provide key differentiator Targeting non-PC customers - not a focus for semi companies Broad base of tier one customers: Specialty DRAM Enterprise SSD Brazilian Market Deals Specialty & Brazil DRAM 84 Storage 16 Brazil 0 Strong historical presence in large defense and industrial SSD markets Achieved $100mm volume run rate Broad IP platform & expertise jump starting push into highly attractive enterprise market Doubling R&D efforts providing competitive advantage Strong Tier 1 OEM momentum and ability to leverage Tier 1 OEM relationships Large market opportunity One of the fastest growing global economies and PC markets Government mandated nationwide Broadband / PC deployment plan (Current penetration <25%) High barriers to entry to establish operations in Brazil Largest IC packaging company in Brazil #1 market share (~40%) Expanding DRAM capacity and rolling out Flash Shakespeare Today 10

Blue Series 0.22 0.025 1.3 0.225 0.19 2 0.35 0.22 3 0.165 0.15 1 0.275 0.025 0.5 0.45 0.04 0.2 Currently served markets exhibit different growth rates, maturity profiles and competitive dynamics Across a Broad Set of Diverse Markets Characterized by Different Growth Rates Shakespeare's $8 billion Market Opportunity ___________________________ Source: Company presentation. Brazil Flash #1 target SSD Enterprise Top 5 target #1 in Brazil DRAM #1 in Specialty Module #1 in Embedded #1 in SSD Defense Gross Margin $1.3bn $2.0bn $3.0bn $500mm $200mm $1bn Denotes $ Market Size 11

Revenue % QoQ Growth Q3 188.459 0.151021180954242 Q4 196.953 4.50708111578646E-02 Q1 237.17 0.204195924916097 Q2 239.137 8.29362904245889E-03 Q3 186.478 -0.220204318026905 Q4 165.587 -0.112029301043555 Q1 174.951 5.65503330575468E-02 Q2 164.497 -5.97538739418466E-02 Q3 167.615 1.89547529742184E-02 Q4 160.666 -4.14581033917012E-02 Q1 140.775 -0.123803418271445 Q2 109.089 -0.225082578582845 Q3 91.645 -0.159906131690638 Q4 99.808 8.90719624638552E-02 Q1 123.093 0.233297932029497 Q2 160.11 0.300723842948015 Q3 201.235 0.256854662419586 Q4 218.652 8.65505503515791E-02 Strong Recent Historical Financial Performance Quarterly Revenue and Q/Q Growth Since IPO ___________________________ Source: Company filings and FactSet. Note: Fiscal year ends in August. Comparables Index includes Micron, OCZ, Radisys, SanDisk, Spansion and STEC. Adj. EBITDA % Margin Q3 17.05125 9.04772390811795E-02 Q4 17.29325 8.78039430727128E-02 Q1 22.82475 0.096237930598305 Q2 23.29775 9.74242798061362E-02 Q3 22.10075 0.118516661482856 Q4 17.19275 0.103829104941813 Q1 20.026 0.114466336288446 Q2 19.094 0.116075065198757 Q3 12.626 7.53273871670197E-02 Q4 10.5 6.53529682695779E-02 Q1 10.262 7.28964659918309E-02 Q2 10.168 9.32082978118784E-02 Q3 5.232 5.70898576027061E-02 Q4 9.893 9.91203109971145E-02 Q1 15.047 0.122240907281486 Q2 28.395 0.17734682405846 Q3 29.752 0.1478 Q4 33.213 0.151898907853576 Indexed Stock Price Performance - LTM Indexed Stock Price Performance - Since IPO FY06 FY07 FY09 FY10 FY08 FY06 FY07 FY09 FY10 FY08 Quarterly EBITDA and Margin Since IPO 12

Mixed Historical Performance vs. Expectations Quarterly Revenue Surprises Since IPO Quarterly Earnings Surprises Since IPO Quarter Rev % Surprise Q3 06 0.097 Q4 06 0.001 Q1 07 0.125 Q2 07 0.016 Q3 07 -0.207 Q4 07 0.073 Q1 08 0.02 Q2 08 -0.115 Q3 08 0.103 Q4 08 -0.004 Q1 09 -0.104 Q2 09 -0.121 Q3 09 -0.084 Q4 09 0.272 Q1 10 0.064 Q2 10 0.124 Q3 10 0.114 Q4 10 0.066 Quarter EPS Surprise Q3 06 0.067 Q4 06 0.056 Q1 07 0.087 Q2 07 0.059 Q3 07 -0.005 Q4 07 0.027 Q1 08 0.036 Q2 08 -0.075 Q3 08 -0.184 Q4 08 -0.512 Q1 09 Q2 09 Q3 09 0.5 Q4 09 Q1 10 0.6 Q2 10 0.704 Q3 10 0.444 Q4 10 0.272 ___________________________ Source: Company filings and FactSet. Note: EPS is non-GAAP, excluding stock-based compensation, restructuring charges and other unusual items. Consensus EPS projection of ($0.01) and reported EPS of $0.02. Consensus EPS projection of ($0.01) and reported EPS of $0.03. Consensus EPS projection of ($0.01) and reported EPS of $0.01. $188.5 $197.0 $237.2 $239.1 $186.5 $165.6 $175.0 $164.5 $167.6 $160.7 $140.8 $109.1 $91.6 $99.8 $123.1 $160.1 $201.2 $218.7 $0.19 $0.23 $0.22 $0.22 $0.22 $0.21 $0.18 $0.17 $0.05 $0.02 $0.02 $0.03 ($0.01) $0.00 $0.08 $0.23 $0.26 $0.29 EPS: Rev ($ mm): NM(1) NM(3) NM(2) (20.7%) 13

Shakespeare Comps SOX 2/3/2006 7.9 10 11.1 2/10/2006 7.7 10.2 11.4 2/17/2006 7.9 10.1 11.6 2/24/2006 7.9 9.9 11.3 3/3/2006 7.7 9.9 11.8 3/10/2006 7.7 9.7 10.9 3/17/2006 7.7 10 10.9 3/24/2006 7.8 10.2 11.1 3/31/2006 8.1 10 11.3 4/7/2006 8.1 9.8 11.9 4/13/2006 8.3 9.8 11.7 4/21/2006 8.3 10 11.7 4/28/2006 8.3 10.6 11.3 5/5/2006 7.4 10.4 11.6 5/12/2006 7.4 9.9 10.7 5/19/2006 6.6 10 10.5 5/26/2006 6.2 10.3 10 6/2/2006 7.3 10.5 10.1 6/9/2006 6.9 9.9 9.2 6/16/2006 6.4 8.8 9.5 6/23/2006 7.1 8.6 9.3 6/30/2006 6.8 9.3 9.3 7/7/2006 6.6 9.1 8.8 7/14/2006 5.8 8.7 8.4 7/21/2006 5.2 8.6 7.7 7/28/2006 5.4 9.3 8.5 8/4/2006 5.7 9.9 8.4 8/11/2006 5.5 10.6 8.4 8/18/2006 6.5 9.4 9.5 8/25/2006 6.5 9.2 9.3 9/1/2006 6.8 9.8 9.6 9/8/2006 6.4 9.8 9.3 9/15/2006 7 9.4 9.7 9/22/2006 7.1 9.1 9.4 9/29/2006 7.4 9.8 9.7 10/6/2006 7 9.3 9.7 10/13/2006 6.7 9.6 10.2 10/20/2006 6.1 8.8 9.5 10/27/2006 6.5 8.1 9.5 11/3/2006 6.3 7.7 9.4 11/10/2006 6.8 7.7 9.6 11/17/2006 7.7 7.7 10.2 11/24/2006 8 7.7 10.3 12/1/2006 8.3 8.8 9.9 12/8/2006 8.9 9.2 10 12/15/2006 8.1 9.3 10 12/22/2006 8.2 9.3 9.6 12/29/2006 8.8 9.9 9.7 1/5/2007 8.5 9.5 9.8 1/12/2007 9.5 9.7 10.2 1/19/2007 7.4 8.7 9.7 1/26/2007 7.6 8.8 9.9 2/2/2007 7.7 8.8 10 2/9/2007 7.7 8.4 10.1 2/16/2007 6.8 8.2 9.7 2/23/2007 7.2 8.6 9.9 3/2/2007 6.4 7.8 9.2 3/9/2007 6.9 8.3 9.5 3/16/2007 6.9 8 9.7 3/23/2007 7 8 10 3/30/2007 7.7 8.1 9.7 4/5/2007 7.7 8.4 9.9 4/13/2007 8.1 8.3 10 4/20/2007 7.6 8.5 10.3 4/27/2007 7.8 8.2 10.4 5/4/2007 7.9 8.2 10.6 5/11/2007 8.9 8.3 10.7 5/18/2007 8.5 8.9 10.6 5/25/2007 8.1 9.2 10.3 6/1/2007 8.6 9.2 10.6 6/8/2007 7.8 8.4 10.5 6/15/2007 8.6 8.5 11 6/22/2007 8.2 8.4 11 6/29/2007 7.8 8.5 11 7/6/2007 7.8 8.5 11.3 7/13/2007 7.9 9.1 11.8 7/20/2007 7.9 9.5 11.7 7/27/2007 6.8 8.8 11.1 8/3/2007 6 8.6 10.8 8/10/2007 6.6 8.6 11.1 8/17/2007 6.6 11.7 10.6 8/24/2007 6.2 11.6 10.8 8/31/2007 6 11.1 11.1 9/7/2007 4.9 11.3 11 9/14/2007 3.9 11.3 10.9 9/21/2007 4.6 11.4 11.2 9/28/2007 4.5 11.9 11.3 10/5/2007 5.4 11.9 11.4 10/12/2007 5.9 11.6 11.3 10/19/2007 6 10.5 10.9 10/26/2007 5.9 11.3 10.3 11/2/2007 5.3 13.8 10.7 11/9/2007 4.6 13 10.1 11/16/2007 5.6 8.9 9.9 11/23/2007 5.4 8.8 9.6 11/30/2007 5.3 10 9.9 12/7/2007 5.1 10.8 10.3 12/14/2007 4.8 9.6 10.1 12/21/2007 6.9 9.1 10.1 6.0x 5.2x Shakespeare Comps SOX 2/3/2006 13.8 24.5 21.32856 2/10/2006 13.5 24.7 21.79452 2/17/2006 13.7 24.6 20.12675 2/24/2006 13.9 24.2 19.71437 3/3/2006 13.9 24.3 20.32129 3/10/2006 13.9 23.3 19.17129 3/17/2006 13.9 23.5 19.19372 3/24/2006 14 24 19.52795 3/31/2006 14.6 23.7 19.5163 4/7/2006 14.7 24 20.09108 4/13/2006 15.1 24 19.84171 4/21/2006 13.3 24.2 19.96319 4/28/2006 13.2 25.3 20.07914 5/5/2006 13.6 25.2 20.42806 5/12/2006 13.5 24.3 19.17187 5/19/2006 12.2 23.2 18.35091 5/26/2006 11.5 23.3 17.70766 6/2/2006 13 23 17.8386 6/9/2006 12.2 22.1 16.5885 6/16/2006 11.5 20.4 16.918 6/23/2006 12.7 20 16.65714 6/30/2006 12.1 20.1 16.88465 7/7/2006 11.7 19.5 16.26295 7/14/2006 10.5 18.3 15.596027 7/21/2006 9.4 17.6 14.82991 7/28/2006 9.7 19.5 15.978845 8/4/2006 10.3 20 15.844253 8/11/2006 9.9 20.5 15.722083 8/18/2006 11.8 20.3 17.731 8/25/2006 11.7 20.4 17.56981 9/1/2006 12.4 21.5 18.24586 9/8/2006 11.6 21.4 17.86535 9/15/2006 12.5 21.1 18.00662 9/22/2006 12.6 20.6 17.62059 9/29/2006 13.1 20.9 18.28268 10/6/2006 12.3 20.4 18.11807 10/13/2006 12 20.9 19.02994 10/20/2006 10.8 19 17.84245 10/27/2006 11.5 18.2 17.72784 11/3/2006 10.9 17.7 17.50491 11/10/2006 11.7 17.6 17.75044 11/17/2006 13.4 18.8 18.65045 11/24/2006 13.9 18.9 18.76495 12/1/2006 14.2 18 18.16048 12/8/2006 15.3 18.6 18.26771 12/15/2006 13.6 19.5 18.52438 12/22/2006 13.7 19.5 17.93358 12/29/2006 14.8 20.1 18.07658 1/5/2007 14.2 19.6 18.22789 1/12/2007 15.8 20 18.94612 1/19/2007 12.6 18.1 18.14017 1/26/2007 12.8 18.2 18.31804 2/2/2007 13 18 18.56289 2/9/2007 13.2 17.2 18.53009 2/16/2007 11.7 18.8 35.21682 2/23/2007 12.3 19.2 34.83131 3/2/2007 10.8 17.9 33.6745 3/9/2007 11.6 18.4 33.77077 3/16/2007 11.7 21 18.70464 3/23/2007 11.8 21.8 19.07084 3/30/2007 12.9 21.6 18.53084 4/5/2007 13 22 18.96776 4/13/2007 13.5 21.6 19.07095 4/20/2007 12.8 25.9 19.87129 4/27/2007 13.2 26.1 20.13352 5/4/2007 13.6 26.1 20.3769 5/11/2007 15.1 26.6 20.569 5/18/2007 14.6 27.5 19.64334 5/25/2007 14 27.8 19.31393 6/1/2007 14.6 28.3 19.80604 6/8/2007 13.3 28.3 19.60631 6/15/2007 14.5 24.5 20.85991 6/22/2007 13.9 24.5 20.941 6/29/2007 13.3 24.5 20.87575 7/6/2007 13.3 24.4 21.66382 7/13/2007 13.4 26.7 22.38019 7/20/2007 13.2 27 381.1656 7/27/2007 11.5 24.8 318.2818 8/3/2007 10.2 23.9 310.4688 8/10/2007 11.2 24.5 335.5772 8/17/2007 11.1 26.9 25.51118 8/24/2007 10.6 26.8 25.87004 8/31/2007 10.2 26.6 26.72881 9/7/2007 8.4 26.4 26.55985 9/14/2007 6.8 26.2 25.92911 9/21/2007 8.4 26 21.74884 9/28/2007 8.4 26.8 21.96925 10/5/2007 9.9 26.4 21.86004 10/12/2007 10.6 25.3 21.55045 10/19/2007 10.5 22.5 24.42739 10/26/2007 10.3 23.6 23.59321 11/2/2007 10 27.8 24.82348 11/9/2007 8.9 25.7 23.18862 11/16/2007 10.4 20.8 18.64826 11/23/2007 9.9 20.5 17.90275 11/30/2007 9.7 22.1 18.32445 12/7/2007 9.5 23.4 19.26894 12/14/2007 9 21.3 18.57353 12/21/2007 11.8 20.6 17.30846 Shakespeare Comps SOX 2/3/2006 0.77 1.72 3.878812 2/10/2006 0.75 1.72 3.956047 2/17/2006 0.77 1.72 3.76197 2/24/2006 0.78 1.72 3.693708 3/3/2006 0.75 1.72 3.813134 3/10/2006 0.75 1.72 3.553716 3/17/2006 0.76 1.42 3.503797 3/24/2006 0.76 1.46 3.573471 3/31/2006 0.79 1.48 3.709225 4/7/2006 0.79 1.54 3.879515 4/13/2006 0.81 1.54 3.821804 4/21/2006 0.8 1.56 3.851197 4/28/2006 0.79 1.67 3.710936 5/5/2006 0.71 1.59 3.830909 5/12/2006 0.71 1.52 3.540652 5/19/2006 0.64 1.48 3.386826 5/26/2006 0.6 1.47 3.21768 6/2/2006 0.71 1.41 3.285711 6/9/2006 0.66 1.32 3.015978 6/16/2006 0.63 1.34 3.088744 6/23/2006 0.69 1.3 3.021366 6/30/2006 0.66 1.3 3.046756 7/7/2006 0.64 1.23 2.907256 7/14/2006 0.57 1.09 2.778519 7/21/2006 0.5 1.08 2.577489 7/28/2006 0.52 1.28 2.814868 8/4/2006 0.55 1.33 2.787961 8/11/2006 0.52 1.34 2.771111 8/18/2006 0.63 1.65 3.08314 8/25/2006 0.63 1.7 3.018996 9/1/2006 0.66 1.92 3.149638 9/8/2006 0.62 1.89 3.052036 9/15/2006 0.69 1.9 3.1673 9/22/2006 0.7 1.78 3.094207 9/29/2006 0.73 1.76 3.188722 10/6/2006 0.68 1.73 3.173818 10/13/2006 0.66 1.77 3.369675 10/20/2006 0.6 1.53 3.207576 10/27/2006 0.64 1.45 3.187283 11/3/2006 0.62 1.43 3.131985 11/10/2006 0.66 1.4 3.167719 11/17/2006 0.76 1.45 3.369539 11/24/2006 0.79 1.46 3.421453 12/1/2006 0.82 1.46 3.333777 12/8/2006 0.88 1.46 3.371538 12/15/2006 0.8 1.36 3.36418 12/22/2006 0.8 1.34 3.253778 12/29/2006 0.87 1.49 3.297341 1/5/2007 0.83 1.47 3.310166 1/12/2007 0.93 1.52 3.482122 1/19/2007 0.7 1.41 3.300224 1/26/2007 0.72 1.42 3.336107 2/2/2007 0.73 1.38 3.379624 2/9/2007 0.73 1.39 3.379362 2/16/2007 0.65 1.37 3.490033 2/23/2007 0.68 1.36 3.5704 3/2/2007 0.61 1.29 3.305227 3/9/2007 0.66 1.32 3.391953 3/16/2007 0.66 1.38 3.373036 3/23/2007 0.67 1.49 3.470342 3/30/2007 0.73 1.49 3.314991 4/5/2007 0.74 1.48 3.399748 4/13/2007 0.77 1.45 3.39001 4/20/2007 0.75 1.43 3.55234 4/27/2007 0.77 1.46 3.571193 5/4/2007 0.78 1.5 3.605788 5/11/2007 0.87 1.52 3.617683 5/18/2007 0.84 1.47 3.52937 5/25/2007 0.8 1.45 3.458412 6/1/2007 0.85 1.48 3.580087 6/8/2007 0.77 1.51 3.5064 6/15/2007 0.85 1.54 3.652841 6/22/2007 0.81 1.57 3.643426 6/29/2007 0.78 1.57 3.672079 7/6/2007 0.78 1.61 3.801245 7/13/2007 0.78 1.73 3.921276 7/20/2007 0.88 1.72 3.743688 7/27/2007 0.76 1.6 3.547163 8/3/2007 0.67 1.6 3.485558 8/10/2007 0.73 1.69 3.533431 8/17/2007 0.73 1.52 3.417886 8/24/2007 0.7 1.51 3.552 8/31/2007 0.68 1.55 3.616813 9/7/2007 0.55 1.5 3.567884 9/14/2007 0.43 1.47 3.552352 9/21/2007 0.51 1.48 3.637604 9/28/2007 0.51 1.54 3.636739 10/5/2007 0.61 1.49 3.709203 10/12/2007 0.66 1.39 3.629681 10/19/2007 0.67 1.27 3.558837 10/26/2007 0.66 1.27 3.4796 11/2/2007 0.59 1.38 3.591328 11/9/2007 0.52 1.26 3.402921 11/16/2007 0.63 1.21 3.373509 11/23/2007 0.6 1.18 3.271747 11/30/2007 0.59 1.34 3.426111 12/7/2007 0.57 1.46 3.602756 12/14/2007 0.54 1.34 3.523025 12/21/2007 0.73 1.28 3.603588 Anecdotally Investors Continue to Discount Shares Historical EV / FTM Revenue Multiples Historical Price / FTM Earnings Multiples ___________________________ Source: FactSet and Wall Street research. Note: Excludes EBITDA multiples >30.0x or <0.0x and P/E multiples >60.0x or <0.0x. Comps include Micron, Radisys, SanDisk, and STEC. Shakespeare FTM EBITDA calculated by adding actual FY D&A for appropriate periods to projected FTM EBIT. Current 1 Yr Avg Since IPO Shakespeare 7.2x 13.0x 12.7x Comps 11.3x 14.3x 17.9x SOX 11.3x 14.7x 29.1x 2.38x 0.48x 1.12x 11.3x 7.2x 11.3x Historical EV / FTM EBITDA Multiples (1) 3.5x Current 1 Yr Avg Since IPO Shakespeare 3.5x 4.1x 4.9x Comps 5.2x 6.2x 12.7x SOX 6.0x 7.2x 9.9x Current 1 Yr Avg Since IPO Shakespeare 0.48x 0.49x 0.49x Comps 1.12x 1.24x 1.31x SOX 2.38x 2.64x 3.06x Oct-10 Oct-10 Oct-10 14

Optimism around focus on growth initiative leveraging dominance in defense / industrial to build a position in high margin enterprise SSD Encouraged by plans to fund promising Flash investment in high growth Brazilian market Expectation that Brazil will continue its solid economic growth coupled with strong PC growth from pent-up consumer demand DRAM ASP pressure across industry appears to have minimal impact on Shakespeare Recent softness in PC and Server demand could put pressure on demand for Shakespeare's products Concerns around weaker DRAM ASPs affecting Shakespeare into early 2011 Customer concentration risk with several large OEM customers representing the majority of sales Market concentration risk given relatively high contribution to revenue from Brazil Increasing competition in SSD market could slow growth in enterprise SSD EPS Consensus Deals Buy 5 Hold 3 Summary Outlook Revenue Consensus Key Themes Analyst Projections n = 8; Median Price Target: $10.25 ($ in millions, except per share values) Positives Negatives ___________________________ Source: FactSet and Bloomberg. Note: Summary outlook and analyst projections only include reports from current period. Wall Street Views on Shakespeare Wall Street remains cautiously optimistic while trying to understand Shakespeare's position in the competitive landscape FY11 FY12 Low 819.5 938.3 Mean 874.7 998.8 High 900 1047.8 FY11 FY12 Low 0.87 1 Mean 0.98 1.18 High 1.15 1.45 15

Transition from semis to Enterprise not fully reflected in coverage universe Shakespeare's Sellside Following Spans Semiconductors and Enterprise Analyst Coverage Bank Name Valuation Methodologies Coverage Industry Coverage Universe Barclays Capital Tim Luke CY11E P/E Semiconductors Citi Jim Suva FY12E P/E EMS/ESC Merriman Curhan Ford Alex Kurtz FY11E P/E Emerging Data Center Technologies Needham Richard Kugele FY11E P/E Disk Drives, IT Distribution, IT Hardware & Software Oppenheimer Gary Hsueh FY11E P/E Semiconductor Cap Equipment and Solar Stifel Nicolaus Kevin Cassidy FY11E P/E Semiconductors ThinkEquity Krishna Shankar CY11E P/E Semiconductors Wedbush Securities Betsy Van Hees CY12E P/E Semiconductors 16

SMOD 7.23113409198848 RSYS 14.0845070422535 STEC 13.3913840513291 CODE 10.8352941176471 SNDK 9.96537027171018 OCZ 7.21951219512195 MU 6.13029827315542 SMOD 5.68821207795705 STEC 19.5413309330098 RSYS 7.5852174904943 SNDK 5.15737827446103 CODE 4.69441522251675 MU 4.0081224026052 OCZ NM SMOD 0.142295309166992 OCZ 0.46658179503501 STEC 0.425431184035278 MU 0.119230535348303 SNDK 0.082068449394904 CODE 5.27028931308469E-02 RSYS 1.60904440867278E-02 SMOD 0.2300533 STEC 0.43736 SNDK 0.4142 CODE 0.358 RSYS 0.346 MU 0.3050767 OCZ 0.2288333 SMOD 0.106332197817775 SNDK 0.25545703247508 STEC 0.182087763103483 CODE 0.144 MU 0.14282626878322 RSYS 0.074 OCZ 0.0669126171875 SMOD 9.56743674673885E-02 SNDK 0.28736818400061 MU 0.275828472331704 CODE 0.244733337836001 STEC 0.116840334127988 RSYS 8.95047968445305E-02 OCZ NM SMOD 0.476423292831137 STEC 1.60177191371305 SNDK 1.36966051432776 CODE 1.09136197315633 MU 0.987780662082298 RSYS 0.668162322024872 OCZ 0.377324136284722 SMOD 3.47189254312049 STEC 7.33798638097865 RSYS 6.64970733333333 OCZ 5.10692355289331 SNDK 4.60445659483296 CODE 4.17056843285751 MU 2.83300319828858 19.6x 46.7% Current Comparable Trading and Operating Metrics ___________________________ Source: FactSet, Company filings, Wall Street research. Market data as of 10/25/2010. Note: "NM" denotes a negative metric. Revenue Growth 11/10 Comparable Operating Metrics 2011 Gross Margin 2011 Operating Margin 42.5% 14.2% EV / CY11 Revenue Comparable Trading Metrics EV / CY11 EBITDA Price / CY11 Earnings EV / CY10 EBITDA - CapEx NM 2010 EBITDA - CapEx Margin NM 11.9% 17

STEC Price 1/1/2005 4.6 1/8/2005 4.38 1/15/2005 4 1/22/2005 3.94 1/29/2005 3.98 2/5/2005 4.12 2/12/2005 3.95 2/19/2005 3.92 2/26/2005 3.97 3/5/2005 4.08 3/12/2005 3.89 3/19/2005 3.96 3/26/2005 3.92 4/2/2005 3.94 4/9/2005 3.76 4/16/2005 3.36 4/23/2005 3.54 4/30/2005 3.73 5/7/2005 3.66 5/14/2005 3.33 5/21/2005 3.49 5/28/2005 3.72 6/4/2005 3.85 6/11/2005 3.81 6/18/2005 3.99 6/25/2005 3.9 7/2/2005 3.79 7/9/2005 3.88 7/16/2005 4.54 7/23/2005 4.4 7/30/2005 4.25 8/6/2005 4.74 8/13/2005 4.42 8/20/2005 4.63 8/27/2005 4.63 9/3/2005 4.74 9/10/2005 4.93 9/17/2005 4.76 9/24/2005 4.72 10/1/2005 4.95 10/8/2005 4.75 10/15/2005 4.56 10/22/2005 4.44 10/29/2005 4.12 11/5/2005 4.32 11/12/2005 3.84 11/19/2005 3.75 11/26/2005 3.8 12/3/2005 3.87 12/10/2005 3.55 12/17/2005 3.74 12/24/2005 3.75 12/31/2005 3.77 1/7/2006 4.22 1/14/2006 4.23 1/21/2006 4.31 1/28/2006 4.2 2/4/2006 4.28 2/11/2006 4.22 2/18/2006 4.18 2/25/2006 4.23 3/4/2006 3.73 3/11/2006 3.4 3/18/2006 3.45 3/25/2006 3.59 4/1/2006 3.76 4/8/2006 3.75 4/15/2006 3.74 4/22/2006 3.96 4/29/2006 4.14 5/6/2006 4.03 5/13/2006 4.07 5/20/2006 4.03 5/27/2006 3.92 6/3/2006 3.95 6/10/2006 3.88 6/17/2006 3.75 6/24/2006 3.7 7/1/2006 3.75 7/8/2006 3.81 7/15/2006 3.88 7/22/2006 5.05 7/29/2006 5.6 8/5/2006 5.78 8/12/2006 5.88 8/19/2006 6.74 8/26/2006 6.5 9/2/2006 7.22 9/9/2006 7.31 9/16/2006 7.64 9/23/2006 8.3 9/30/2006 9.11 10/7/2006 9.11 10/14/2006 9.29 10/21/2006 8.51 10/28/2006 8.52 11/4/2006 8 11/11/2006 8.39 11/18/2006 9.13 STEC Gross Margin 12/31/2004 0.179 0 1/7/2005 0.179 1/14/2005 0.179 1/21/2005 0.179 1/28/2005 0.179 2/4/2005 0.179 2/11/2005 0.179 2/18/2005 0.179 2/25/2005 0.179 3/4/2005 0.179 3/11/2005 0.179 3/18/2005 0.179 3/24/2005 0.179 4/1/2005 0.179 4/8/2005 0.179 4/15/2005 0.179 4/22/2005 0.179 4/29/2005 0.179 5/6/2005 0.179 5/13/2005 0.179 5/20/2005 0.179 5/27/2005 0.179 6/3/2005 0.179 6/10/2005 0.179 6/17/2005 0.179 6/24/2005 0.179 7/1/2005 0.182 7/8/2005 0.182 7/15/2005 0.182 7/22/2005 0.182 7/29/2005 0.182 8/5/2005 0.182 8/12/2005 0.182 8/19/2005 0.182 8/26/2005 0.182 9/2/2005 0.182 9/9/2005 0.182 9/16/2005 0.182 9/23/2005 0.182 9/30/2005 0.207 10/7/2005 0.207 10/14/2005 0.207 10/21/2005 0.207 10/28/2005 0.207 11/4/2005 0.207 11/11/2005 0.207 11/18/2005 0.207 11/25/2005 0.207 12/2/2005 0.207 12/9/2005 0.207 12/16/2005 0.207 12/23/2005 0.207 12/30/2005 0.181 1/6/2006 0.181 0 1/13/2006 0.181 1/20/2006 0.181 1/27/2006 0.181 2/3/2006 0.181 2/10/2006 0.181 2/17/2006 0.181 2/24/2006 0.181 3/3/2006 0.181 3/10/2006 0.181 3/17/2006 0.181 3/24/2006 0.181 3/31/2006 0.193 4/7/2006 0.193 4/13/2006 0.193 4/21/2006 0.193 4/28/2006 0.193 5/5/2006 0.193 5/12/2006 0.193 5/19/2006 0.193 5/26/2006 0.193 6/2/2006 0.193 6/9/2006 0.193 6/16/2006 0.193 6/23/2006 0.193 6/30/2006 0.2 7/7/2006 0.2 7/14/2006 0.2 7/21/2006 0.2 7/28/2006 0.2 8/4/2006 0.2 8/11/2006 0.2 8/18/2006 0.2 8/25/2006 0.2 9/1/2006 0.2 9/8/2006 0.2 9/15/2006 0.2 9/22/2006 0.2 9/29/2006 0.205 10/6/2006 0.205 10/13/2006 0.205 10/20/2006 0.205 10/27/2006 0.205 11/3/2006 0.205 11/10/2006 0.205 11/17/2006 0.205 STEC has repositioned its model to high growth embedded SSD end markets STEC Case Study Stock Price and Gross Margin Business Overview Consumer (51% of revenue) DRAM: Used in PCs, notebooks, servers and high performance computing Storage: HDDs for consumers and small businesses OEM (49% of revenue) Flash: Wide range of embedded storage devices for OEMs DRAM: Stacked memory modules and solutions for high-end systems Operating Performance Gross Margin: 18% - 20% Comparable Companies Market Emphasis Exposure to highly volatile consumer memory products Optimism around increasing focus on flash products for OEMs Past (2005) Present (2010 YTD) Business Overview OEM (100% of revenue) SSD/Flash (79% of revenue): High performance enterprise-class data storage Flash Cards and Modules: Wide portfolio of compact, reliable products used in high performance storage applications DRAM (21% of revenue): Used in high performance computing, comms and industrial apps Operating Performance Gross Margin: 35% - 40% Comparable Companies Market Emphasis Excitement around potential growth resulting from enterprise SSD adoption Transition to MLC NAND seen as a driver of margin improvement / 10/25/2010 2/9/07: Divested lower-margin Consumer Division for $43 million 18

Preliminary Valuation Analysis

Start Length End LBO Analysis 9.86 1.99 11.85 Discounted Cash Flow Analysis 10.1885715818939 4.1140889572244 14.3026605391183 30-Day 7.99384625 1.87062475 9.864471 1-Day 9.48024 1.98072 11.46096 Premiums Paid LTM EBITDA 8.60191737076307 3.61805509316521 12.2199724639283 LTM Revenue 5.79380059424417 4.624388250376 10.4181888446202 Precedent Transaction Analysis CY 2011E P/E 7.31835412354351 4.18191664202486 11.5002707655684 CY 2010E EBITDA - CapEx 5.58801912197684 2.24972027680747 7.83773939878431 Comparable Company Analysis Analyst Price Targets 7.08548350815889 4.42842719259931 11.5139107007582 52-Week Range 3.48 5.03 8.51 Preliminary Summary Valuation Shakespeare Share Price Notes Current Price (10/25/10): $7.56 52-Week Low (10/28/09) and High (4/14/10) Analyst Price Targets discounted at 13.4% cost of equity 4.0 - 6.0x CY2010E EBITDA - CapEx Multiple Targeting 15% to 25% IRR 5.0x 5 year FTM EBITDA exit multiple 0.40x - 0.80x LTM Revenue 25.4% - 51.6% premium to 1-day 23.5% - 52.4% premium to 30-day trading average ___________________________ Source: FactSet, Bloomberg, Company filings, Wall Street research, IBES consensus estimates and Barclays Capital Investment Banking estimates. Note: Market data as of 10/25/10. Net cash used to calculate equity value as of 8/27/10, except for DCF and LBO which assume balance sheet from 2/27/11 transaction close. Based on analyst range of $8.00 to $13.00, discounted to 10/26/10. 7.0x - 11.0x CY2011E P/E Multiple 4.0x - 6.0x Forward EBITDA Multiple and 11.0% - 14.0% WACC 5.0x - 7.5x LTM EBITDA (1) 19

Transaction Pricing Matrix Purchase Price Ratio ($ in millions, except per share amounts) ___________________________ Source: Company filings and Wall Street research. Balance sheet data as of 8/27/10. 20

Precedent Transactions ___________________________ Source: Company filings and FactSet. 21

1 Day 30 Day 0.176017064930008 0.206138482508019 0.34747609774005 0.375336285312191 0.272666721438464 0.311159001036321 0.441623960592585 0.460408827561857 1 Day 30 Day 0.098425 0.173425 0.398760714285714 0.443111904761905 0.2284 0.31865 0.5486 0.535425 Premiums Paid Domestic Technology M&A Transactions 2006 - 2010 YTD between $300M and $1B in value (1) Domestic Technology M&A Transactions 2009 - 2010 YTD between $300M and $1B in value (2) ___________________________ Source: SDC, October 2010. Note: 30 Day denotes premium to 30 day trading average. Analysis includes 148 transactions. Analysis includes 36 transactions. Analysis includes 82 transactions. First Quartile Mean Median Third Quartile Global Technology Take Private Transactions 2009 - 2010 YTD (3) 1 Day 30 Day 0.254356795960994 0.235285393807749 0.497568795598717 0.51958732774575 0.336558897915279 0.37712735869479 0.515651280295439 0.524186265550466 22

Discounted Cash Flow Analysis Valuation ___________________________ Source: Wall Street research and Barclays Capital Investment Banking estimates. Note: Assumes midpoint convention for annual cash flows which are discounted to 2/27/11 for illustrative purposes. Assumes net cash of $82.1 mm at 2/27/11. 1. EBIT and EBITDA adjusted to exclude stock-based compensation and other non-cash expenses. Summary DCF Commentary 2011 and 2012 based on broker consensus Lower longer term growth rate to reach a 5 year CAGR at the lower end of mgmt. target FY 2010 Non-GAAP tax rate from filings, projections converge on mgmt. LT target range No margin expansion Higher margin enterprise SSD offset by higher R&D investments and low- margin flash 23

Illustrative LBO Transaction Exit IRR Analysis Assumes purchase at $10.50 per share (39% premium) to current stock price, implying an entrance multiple of EV/CY10 Adj. EBITDA of ~6.1x (4.9x FTM) with new debt of $175 mm of TL-B and $200 mm of senior HY notes Pro Forma Capitalization Table ___________________________ Source: Wall Street research and Barclays Capital Investment Banking estimates. Note: Assumes interest rate of L+525 on Term Loan B with 1.75% LIBOR floor and 10.00% Senior Notes. IRR calculated based on completion of transaction on 2/27/2011. Transaction expenses include cost of retiring existing senior floating rate notes at 101, notes redeemable at par after April 1, 2011. LBO Summary Sources and Uses 24

Financing Considerations The debt markets are highly attractive, and readily able to provide acquisition financing Over $247 billion of new high yield and $178 billion of leveraged loans issued year to date, surpassing that for all of 2009, a record breaking year for the high yield market 10.1% of deals in 2010 have been for LBO financing, with an aggregate volume of ~$40 billion Middle market LBO financing activity has been active with a number of technology-related issues in 2010 Rates have dropped to all-time levels, with the high yield index yielding 7.44% Semiconductor yields in particular have improved dramatically with recovery in the semis cycle Barclays Capital believes that the LBO debt market would be highly receptive to an offering by Shakespeare Shakespeare has demonstrated the strength and resilience of its business, having rebounded dramatically from the semiconductor cycle Critical to achieving best execution is demonstrating the sustainability of continued improvements in Shakespeare's operating model, and ability to weather the next downturn Based on our preliminary analysis, we believe Shakespeare can support leverage levels of 3.5x - 4.0x LTM EBITDA at the time of a transaction Sophisticated investors both on the private equity and debt market side recognize that semis is a cyclical business and leverage needs to be manageable, especially in LBO situations Critical in demonstrating the thesis behind a Shakespeare LBO is the amount of equity being put into a transaction Acquisition multiple reaffirm valuations, providing support for increased leverage Debt investors would want a healthy equity cushion behind them, at least in the 40% area Sponsors have available to them a number of financing structures and markets in order to support an LBO Each alternative has its merits and considerations, such as cost of capital versus being subject to financial maintenance covenants For illustration, we have assumed a structure of $175 million of 1st Lien Term Loans and $200 million of High Yield Bonds Could also finance through combinations such as: $300 million of 1st Lien Term Loans and $75 million of Mezzanine (e.g., 2nd Lien Term Loans) $375 million of Senior Secured High Yield Bonds The acquisition finance markets are exceedingly robust and would be very receptive to an offering by Shakespeare 25

Issues Before the Special Committee

Special Committee and independent advisors; "Entire Fairness" standard Power to say "No" Potential for management involvement Minimize operational disruption Timing considerations Status quo: value attainable in the near, medium and long term LBO: value attainable Strategic acquisition: likelihood and value Other alternatives: recapitalization, alternative capital investment plan Impact of rejecting a potential proposal Disclosure of potential offers Auction vs. negotiation (market check) Optimize terms, certainty of any transaction pursued Value Potential Tactics Special Committee Process Key Issues Facing the Special Committee Barclays Capital will work with counsel to assist the Special Committee in assessing the situation and executing Special Committee strategies 26

Assist the Special Committee in developing a strategic approach to achieve objectives Assess market situation and perceptions to assist in evaluation and proper recommendation Evaluate timing and content of communications with the bidding group Actively monitor shareholder feedback Assess prospects of all relevant businesses Coordinate and complete due diligence Perform rigorous public and private market valuation of Shakespeare's businesses Review business rationale and expected benefits of proposed transaction Frame recommendations and develop proper strategy around ensuring that the process is complete and fair Evaluate transaction and capital structure - provide any necessary capital markets advice relevant to the proposed transaction Negotiate structure and terms of a potential transaction with the bidding group to ensure public shareholders receive a fair price Deliver opinions supported by Barclays Capital' rigorous internal review process Barclays Capital's Fairness Opinion Committee members average 20+ years of investment banking transaction experience Discipline and integrity of Barclays Capital's process strengthens recommendation Valuation Structure / Negotiation Fairness Opinion Strategy Barclays Capital's Role Barclays Capital has great experience in assisting Special Committees in fulfilling their fiduciary obligations in conflict of interest transactions 27

Process Roadmap for Special Committee Form Special Committee Hire legal advisors Hire financial advisors Develop timetable and agree on objectives Obtain access to critical information Receive formal terms of proposal - form of agreement, structure, etc. Allocate adequate time of review and analysis while keeping in mind potential disclosure obligations Evaluate the potential alternatives including stand alone strategy or other possible transactions Develop a response to the proposal Likely result will be: Negotiation with bidding group Pursuit of alternative transaction Rejection of proposal, or Other Finalize documentation of a transaction (if so determined) Receive opinion of financial advisors to support the Committee's findings Coordinated and scripted communication with public Phase I - Organize Phase II - Analyze Phase III - Optimize Status ? ? Underway We believe that a 6 - 10 week process will appropriately balance the competing priorities of speed / minimizing corporate distraction with thoughtful and deliberate exploration of alternatives 2 weeks 3 weeks 3 weeks 28

Sponsor Fund Size Relevant Acquisitions and Portfolio Companies Founded: 1985 Total assets: $16 bn Founded: 1999 Total assets: $5 bn Founded: 2000 Total assets: $9 bn Founded: 1999 Total assets: $13 bn Founded: 1992 Total assets: $50 bn Founded: 1997 Total assets: $2 bn Select Financial Buyers ___________________________ Source: Company website, FactSet, Capital IQ, Hoover's, OneSource. / 29

Potential Strategic Buyers for Shakespeare Complementary product roadmaps SanDisk in August launched its first product in embedded SSD category Shakespeare's announced new strategic move into the Flash packaging focusing on Micro SD cards, SD cards, and USBs Strategic opportunity to leverage Shakespeare's current presence to penetrate Brazil market by offering full manufacturing capability and shorter lead times Specialized DRAM business not a clear fit Expand downstream by further integrating Shakespeare's highly differentiated specialty DRAM capabilities to drive higher margins and top line growth Synergistic product offering: Shakespeare's XceedIOPS SAS solution currently ships with Micron's MLC Flash components Opportunity to leverage Shakespeare's presence and relationships with Tier 1 OEMs to cross sell into the Brazil's high growth end markets High volume focused NA #1 global memory module vendor - opportunity to acquire the closest competitor and further consolidate the market Shakespeare's dominant position in Brazil provides instant access to highly attractive end markets Access to Shakespeare's IP and expertise in enterprise-class SSS solutions to complement its consumer/computing SSS offering Privately held and has not executed M&A historically Expand downstream by further integrating Shakespeare's highly differentiated specialty DRAM capabilities to drive higher margins and top line growth Developing a new SSD controller in partnership with Seagate - enterprise-class SSD's slated for a "mid-2012" release Has not historically executed on M&A Company Strategic Rationale Key Metrics ___________________________ Source: FactSet and I/B/E/S consensus estimates. Data as of 10/25/2010. ($ in millions) 30

Appendices

Leveraged Finance

With yields at historical lows, there has been a surge of primary issue in the markets Leveraged Finance Market Overview HY Index 1/30/1987 12.2 2/27/1987 12 3/31/1987 12 4/30/1987 12.7 5/29/1987 12.7 6/30/1987 12.7 7/31/1987 12.7 8/31/1987 12.8 9/30/1987 13.6 10/30/1987 14.5 11/30/1987 14.1 12/31/1987 13.9 1/29/1988 13.5 2/29/1988 13.1 3/31/1988 13.5 4/29/1988 13.5 5/31/1988 13.7 6/30/1988 13.7 7/29/1988 13.7 8/31/1988 13.9 9/30/1988 13.8 10/31/1988 13.8 11/30/1988 13.8 12/30/1988 14 1/31/1989 13.8 2/28/1989 14 3/31/1989 14.5 4/28/1989 14.6 5/31/1989 14.2 6/30/1989 14.2 7/31/1989 14.3 8/31/1989 14.4 9/29/1989 15 10/31/1989 15.8 11/30/1989 16 12/29/1989 16.1 1/31/1990 16.5 2/28/1990 17 3/30/1990 17 4/30/1990 17.5 5/31/1990 17.7 6/29/1990 16.9 7/31/1990 16.5 8/31/1990 17.7 9/28/1990 19.6 10/31/1990 20.9 11/30/1990 20.8 12/31/1990 20.9 1/31/1991 20.5 2/28/1991 18 3/28/1991 16 3/29/1991 16 4/30/1991 15.5 5/31/1991 15.2 6/28/1991 14.5 7/31/1991 14.1 8/30/1991 13.8 9/30/1991 13.6 10/31/1991 13.2 11/29/1991 13.1 12/31/1991 13.4 1/31/1992 12.5 2/28/1992 11.6 3/31/1992 11.3 4/30/1992 11.4 5/29/1992 11.6 6/30/1992 11.6 7/31/1992 11.4 8/31/1992 10.8 9/30/1992 10.7 10/30/1992 11.1 11/30/1992 11 12/31/1992 10.9 1/29/1993 9.8 2/26/1993 9.4 3/31/1993 9.3 4/30/1993 9.2 5/28/1993 9.1 6/30/1993 8.8 7/30/1993 8.7 8/31/1993 9 9/30/1993 9.2 10/29/1993 9 11/30/1993 9.1 12/31/1993 9.1 1/31/1994 8.6 2/28/1994 8.9 3/31/1994 9.9 4/29/1994 10.3 5/31/1994 10.4 6/30/1994 10.5 7/29/1994 10.4 8/31/1994 10.4 9/30/1994 10.6 10/31/1994 10.8 11/30/1994 11.2 12/30/1994 11.3 1/31/1995 11.2 2/28/1995 10.8 ... driving High Yield rates to historic lows ... Today: 7.4% 2002 - 1H07 HY Index YTW Avg.: 7.7% IG Index 10 yr Treasury DJIA 1/4/2010 4.733296 3.83988 10583.96 1/5/2010 4.615417 3.75448 10572.02 1/6/2010 4.622294 3.80678 10573.68 1/7/2010 4.621202 3.82058 10606.86 1/8/2010 4.591156 3.80717 10618.19 1/11/2010 4.581961 3.81756 10663.99 1/12/2010 4.52038 3.71762 10627.26 1/13/2010 4.581823 3.78201 10680.77 1/14/2010 4.529547 3.73138 10710.55 1/15/2010 4.496058 3.67537 10609.65 1/19/2010 4.535046 3.70649 10725.43 1/20/2010 4.504338 3.65808 10603.15 1/21/2010 4.457154 3.60794 10389.88 1/22/2010 4.488853 3.59654 10172.98 1/25/2010 4.521031 3.63083 10196.86 1/26/2010 4.512584 3.62944 10194.29 1/27/2010 4.522902 3.64304 10236.16 1/28/2010 4.519912 3.65618 10120.46 1/29/2010 4.4596 3.6104 10067.33 2/1/2010 4.543049 3.6511 10185.53 2/2/2010 4.51608 3.63566 10296.85 2/3/2010 4.546762 3.69985 10270.55 2/4/2010 4.495897 3.60676 10002.18 2/5/2010 4.480498 3.54523 10012.23 2/8/2010 4.538924 3.59151 9908.39 2/9/2010 4.601752 3.63415 10058.64 2/10/2010 4.649744 3.70508 10038.38 2/11/2010 4.668644 3.7297 10144.19 2/12/2010 4.615456 3.69185 10099.14 2/16/2010 4.609783 3.66354 10268.81 2/17/2010 4.659424 3.74112 10309.24 2/18/2010 4.679213 3.80211 10392.9 2/19/2010 4.659478 3.78023 10402.35 2/22/2010 4.631026 3.79649 10383.38 2/23/2010 4.544387 3.68952 10282.41 2/24/2010 4.549778 3.69378 10374.16 2/25/2010 4.510649 3.64184 10321.03 2/26/2010 4.474263 3.59103 10325.26 3/1/2010 4.482741 3.6051 10403.79 3/2/2010 4.465493 3.61261 10405.98 3/3/2010 4.473684 3.62201 10396.76 3/4/2010 4.46802 3.60506 10444.14 3/5/2010 4.515046 3.68058 10566.2 3/8/2010 4.506387 3.70907 10552.52 3/9/2010 4.493091 3.69957 10564.38 3/10/2010 4.504086 3.7186 10567.33 3/11/2010 4.513315 3.71862 10611.84 3/12/2010 4.501055 3.70723 10624.69 3/15/2010 4.479368 3.70439 10642.15 3/16/2010 4.428794 3.65169 10685.98 3/17/2010 4.411487 3.64269 10733.67 3/18/2010 4.43419 3.67303 10779.17 3/19/2010 4.452839 3.68731 10741.98 3/22/2010 4.43849 3.66165 10785.89 3/23/2010 4.440832 3.67686 10888.83 3/24/2010 4.559282 3.82827 10836.15 3/25/2010 4.59555 3.89951 10841.21 3/26/2010 4.547331 3.85407 10850.36 3/29/2010 4.532967 3.86235 10895.86 3/30/2010 4.524694 3.86725 10907.42 3/31/2010 4.483888 3.83339 10856.63 4/1/2010 4.503164 3.85925 10927.07 4/2/2010 4.573651 3.94704 10927.07 4/5/2010 4.610896 3.99266 10973.55 4/6/2010 4.587913 3.97112 10969.99 4/7/2010 4.491216 3.8628 10897.52 4/8/2010 4.514054 3.89302 10927.07 4/9/2010 4.505769 3.88734 10997.35 4/12/2010 4.455934 3.84459 11005.97 4/13/2010 4.423397 3.80876 11019.42 4/14/2010 4.447531 3.85489 11123.11 4/15/2010 4.403545 3.84667 11144.57 4/16/2010 4.32629 3.77027 11018.66 4/19/2010 4.391954 3.80609 11092.05 4/20/2010 4.382511 3.79838 11117.06 4/21/2010 4.324416 3.7366 11124.92 4/22/2010 4.358057 3.77039 11134.29 4/23/2010 4.404257 3.81555 11204.28 4/26/2010 4.405391 3.81413 11205.03 4/27/2010 4.321093 3.6896 10991.99 4/28/2010 4.412952 3.77155 11045.27 4/29/2010 4.343031 3.72715 11167.32 4/30/2010 4.270763 3.66183 11008.61 5/3/2010 4.352162 3.70411 11151.83 5/4/2010 4.287896 3.61209 10926.77 5/5/2010 4.274288 3.54737 10868.12 5/6/2010 4.229787 3.39659 10520.32 5/7/2010 4.36136 3.43019 10380.43 5/10/2010 4.394876 3.53588 10785.14 5/11/2010 4.437148 3.53586 10748.26 5/12/2010 4.438153 3.56906 10896.91 5/13/2010 4.415669 3.56269 10782.95 5/14/2010 4.310051 3.43951 10620.16 5/17/2010 4.348526 3.47108 10625.83 5/18/2010 4.278623 3.37839 10510.95 5/19/2010 4.333333 3.35808 10444.37 5/20/2010 4.298612 3.26086 10068.01 5/21/2010 4.291978 3.19696 10193.39 5/24/2010 4.35287 3.22779 10066.57 Volatile equity markets and yields in treasuries and IG at all-time lows ... ... has investors seeking yield in the leveraged finance markets ... ... providing optimal conditions for issuers to tap the primary markets HY New Issue Volume Leveraged Loan Volume 6/1/2009 16.875 3.33 7/1/2009 17.446 3.85 8/1/2009 9.824 3.64 9/1/2009 23.073 9.62 10/1/2009 22.271 6.78 11/1/2009 26.134 10.03 12/1/2009 20.602 7.69 1/1/2010 22.903 12.82 2/1/2010 15.1495 11.63 3/1/2010 40.5667 19.43 4/1/2010 38.072 26.02 5/1/2010 7.7162 22.66 6/1/2010 9.567 17.11 7/1/2010 20.0869 13.91 8/1/2010 24.6721 8.17 9/10/2010 39.453 31.47 MTD 29.165 16.66 2009A HY Volume: $182 billion 2010E: $240 billion Date HY Bonds Leveraged Loans Jan-10 1572 827 Feb-10 -1389 779 Mar-10 2245 869 Apr-10 1728 1643 May-10 -3553 237 Jun-10 592 357 Jul-10 2453.165 263.713 Aug-10 1523 406 Sep-10 2483 1008.4 MTD 1519.1 1077.4 YTD HY Mutual Fund Flows: +9.2 billion YTD Lev. Loans: +7.4 billion 31

Semiconductor Debt Trading Levels Current Trading Levels LTM Trading Levels STATS 7.50% Sr. Notes - 5.3% AMD 8.125% Sr. Notes - 6.3% Amkor 7.375% Sr. Notes - 6.7% Date STATS 7.5% Amkor 7.375% AMD 8.125% AMD 7.75% Magnachip 10.5% Freescale 9.25% Freescale 10.125% Freescale 10.75% NXP 9.5% NXP 9.75% 12/31/2009 0.08254 0.14798 0.1326 1/4/2010 0.07882 0.14395 0.1305 1/5/2010 0.07882 0.13808 0.1278 1/6/2010 0.07776 0.13555 0.1257 1/7/2010 0.07775 0.13336 0.1244 1/8/2010 0.07775 0.13181 0.1244 1/11/2010 0.07881 0.13182 0.1244 1/12/2010 0.07881 0.13245 0.1258 1/13/2010 0.07881 0.13247 0.1258 1/14/2010 0.0788 0.13467 0.1272 1/15/2010 0.08145 0.13786 0.1286 1/19/2010 0.08188 0.13949 0.1286 1/20/2010 0.08188 0.14247 0.128 1/21/2010 0.08188 0.1465 0.13 1/22/2010 0.0832 0.15308 0.1386 1/25/2010 0.0832 0.15666 0.1386 1/26/2010 0.08298 0.15417 0.1379 1/27/2010 0.08298 0.15207 0.1365 1/28/2010 0.08094 0.14965 0.1351 1/29/2010 0.08094 0.1476 0.1351 2/1/2010 0.08188 0.14761 0.1358 2/2/2010 0.08144 0.1483 0.1358 2/3/2010 0.08144 0.14697 0.1344 2/4/2010 0.08232 0.14904 0.1373 2/5/2010 0.08364 0.1561 0.1448 2/8/2010 0.08364 0.15976 0.1448 2/9/2010 0.08342 0.15904 0.1448 2/10/2010 0.08544 0.16546 0.1495 2/11/2010 0.08454 0.17328 0.1495 2/12/2010 0.08454 0.1733 0.1495 2/16/2010 0.08544 0.17015 0.148 2/17/2010 0.08276 0.16632 0.145 2/18/2010 0.08276 0.1618 0.142 2/19/2010 0.08276 0.15922 0.1376 2/22/2010 0.08232 0.15668 0.1333 2/23/2010 0.07984 0.15925 0.1333 2/24/2010 0.07929 0.16007 0.1341 2/25/2010 0.07929 0.15935 0.1363 2/26/2010 0.07929 0.15716 0.1292 3/1/2010 0.07929 0.15216 0.1292 3/2/2010 0.07902 0.14593 0.1264 3/3/2010 0.07766 0.14326 0.1264 3/4/2010 0.07766 0.1426 0.1251 3/5/2010 0.07551 0.14029 0.1224 3/8/2010 0.07285 0.13899 0.119 3/9/2010 0.07285 0.13868 0.119 3/10/2010 0.07311 0.13741 0.1184 3/11/2010 0.0731 0.13839 0.1197 3/12/2010 0.0731 0.13873 0.1184 3/15/2010 0.07336 0.13874 0.1197 3/16/2010 0.07442 0.13941 0.1204 3/17/2010 0.07441 0.13911 0.1185 3/18/2010 0.07441 0.13716 0.1185 3/19/2010 0.07414 0.13524 0.1185 3/22/2010 0.0744 0.13621 0.1205 3/23/2010 0.07414 0.13623 0.1172 3/24/2010 0.07413 0.13529 0.1152 3/25/2010 0.07439 0.1337 0.1113 3/26/2010 0.07596 0.13268 0.1106 3/29/2010 0.076 0.12777 0.1007 3/30/2010 0.07545 0.12506 0.0983 3/31/2010 0.07545 0.1272 0.0983 4/1/2010 0.07599 0.12844 0.1007 4/5/2010 0.07653 0.12752 0.1007 4/6/2010 0.07626 0.12815 0.101 4/7/2010 0.07762 0.12694 0.1007 4/8/2010 0.07762 0.12543 0.102 4/9/2010 0.07761 0.10047 0.12483 0.1013 4/12/2010 0.07761 0.10047 0.08949 0.12423 0.0995 4/13/2010 0.07734 0.10047 0.09112 0.12394 0.0995 4/14/2010 0.07651 0.10046 0.08975 0.12186 0.0995 4/15/2010 0.07597 0.09784 0.08975 0.1198 0.0983 4/16/2010 0.07597 0.09629 0.08975 0.1204 0.1014 4/19/2010 0.07488 0.09577 0.08975 0.12159 0.0983 4/20/2010 0.07488 0.095 0.09317 0.12219 0.0983 4/21/2010 0.07433 0.09473 0.08892 0.11925 0.0977 4/22/2010 0.07433 0.09473 0.08946 0.11896 0.0995 4/23/2010 0.07433 0.09473 0.08729 0.11463 0.0971 4/26/2010 0.07459 0.09447 0.08541 0.1104 0.0965 4/27/2010 0.07378 0.09421 0.08621 0.10957 0.0971 4/28/2010 0.07458 0.09419 0.08728 0.11014 0.0971 4/29/2010 0.0754 0.09394 0.08674 0.10931 0.0995 4/30/2010 0.0754 0.09419 0.08673 0.10959 0.1001 5/3/2010 0.0714 0.07649 0.09418 0.087 0.10987 0.1001 5/4/2010 0.0714 0.07704 0.09418 0.08781 0.11015 0.102 5/5/2010 0.0727 0.07704 0.09468 0.08998 0.11383 0.1032 5/6/2010 0.07348 0.07759 0.0957 0.09338 0.11876 0.1096 5/7/2010 0.07348 0.08235 0.09829 0.09544 0.12505 0.1149 5/10/2010 0.07348 0.08555 0.09829 0.09315 0.12415 0.1135 5/11/2010 0.07437 0.08509 0.09881 0.09429 0.12476 0.1162 5/12/2010 0.0748 0.08372 0.09933 0.09135 0.12176 0.1142 5/13/2010 0.0748 0.08066 0.09932 0.09025 0.1188 0.1123 5/14/2010 0.07758 0.07842 0.10038 0.09135 0.12088 0.1163 5/17/2010 0.07955 0.08191 0.09985 0.09292 0.12451 0.1203 5/18/2010 0.07955 0.08146 0.09985 0.0927 0.12821 0.121 5/19/2010 0.07955 0.08146 0.09984 0.09269 0.13363 0.1211 5/20/2010 0.07955 0.08304 0.09984 0.09544 0.14428 0.1317 5/21/2010 0.08178 0.08442 0.09983 0.09637 0.14498 0.1376 5/24/2010 0.08313 0.08373 0.09983 0.09684 0.14396 0.1369 Debt yields for semiconductor credits continue to tighten alongside the broader market MagnaChip 10.50% Sr. Notes - 9.6% Freescale 10.125% Sr. Sub. Notes-10.9% Freescale 10.75% Sr. Notes-10.0% NXP 9.5% Sr. Notes - 8.2% YTW 32

The LBO financing markets have been receptive to a range of technology-related businesses Mid-Sized Technology-Related LBO Activity Recent Mid-Sized Technology-Related LBO Transactions 33

Ownership Profile

Shakespeare Ownership Overview ___________________________ Source: LionShares data as of 10/25/10. Percentage owned based on common shares outstanding. Growth includes GARP and Aggressive Growth. Value includes value and deep value investors. 2Q10 Ownership and Investor Style Breakdown (2) Current Ownership Summary Top 10 Institutional Shareholders and Insiders (1) Top 10 Institutional Shareholders and Insiders Evolution Top ten institutional and insider holders have ~47% stake Type Amount Growth 97 Value 74 Index 5 Yield 3 Type Amount Institution 82.08 Insider 7.95 Retail 9.97 34

Special Committee Decision Framework and Go-Shop Overview

Internal Due Diligence, Valuation and Alternatives Assessment (1 - 2 weeks) High Level Diligence (1 - 2 weeks) Reject Offers "Just Say No" Status Quo Negotiations with third party (1 week) Accept (Announce) / Reject Special Committee Decision Framework Barclays Capital will help frame the issues and provide the Special Committee with the context and tools to determine a course of action Negotiate Initial Offer (1 week) Detailed Due Diligence and Contracts (2 - 3 weeks) Stop Bankers Barclays Capital leverage finance for leverage view only Mgmt. SWAT Execute NDAs with Sponsors Begin preparing dataroom 3 - 6 Sponsors Consider process confidentiality as well as Sponsor need to partner No financing sources Grant limited access to data Evaluate Offers (1 week) Indications of Interest Evaluate Strategic participation Assess probabilities, feasibilities, synergies, impact on business, speed, confidentiality and competitive impact on process Decide Go / No Go Focused buyer group Financing sources, on limited basis Full dataroom access Refine SPA and schedules Circulate draft SPA Final bids (1 - 2 parties) Review financing commitment partners Key contractual issues (go-shop, break-up Fees, MAC, closing conditions) Decide Go / No Go Fairness opinion Script communication to public Sign SPA Announce Transaction Cont. Sale Process Organize Analyze Optimize 35

In the first modern go-shop to result in a superior proposal, Barclays Capital advised the Special Committee of Triad Hospitals in its negotiations with CCMP and Goldman Sachs Capital Partners (GSCP) These negotiations resulted in an agreement by CCMP and GSCP to acquire Triad for $6.4 billion or $50.25 per share The negotiations also provided Triad the ability to solicit alternative proposals during a 40-day post- signing go-shop period During the go-shop period, Barclays Capital contacted numerous parties and ultimately negotiated a superior transaction with Community Health Systems On March 19, 2007, Community Health agreed to acquire Triad for $6.8 billion or $54.00 per share, a premium of 7.5% to the original proposal by CCMP and GSCP at a premium of 24.8% to the unaffected price - the go-shop created $400 million of value for Triad shareholders Special Committee Advisor has been acquired by In 2009, Barclays Capital conducted a negotiated sale of the iShares business owned by Barclays Plc to CVC Capital Partners for $4.4 billion which was announced in April 2009 It was critical to secure the CVC Capital transaction but also critical to provide Barclays Plc the ability to entertain proposals to generate more shareholder value To provide this flexibility, Barclays Capital negotiated a 45-day go-shop period allowing it to solicit alternative proposals for iShares or related businesses, including Barclays Wealth; this is a rare example of a go-shop feature negotiated in the disposal of a captive subsidiary In June 2009, Barclays entered into a transaction to sell Barclays Wealth (including iShares) to BlackRock for $13.5 billion Expertise in Conducting "Go-Shops" to Maximize Shareholder Value Financial Advisor has been acquired by Notable Successful Go-Shops Conducted by Barclays Capital 36

Time Period to Solicit Alternative Proposals Absolute number of days Preparation of seller Prospective buyers identified and contacted immediately following announcement Confidentiality agreements distributed and negotiated immediately Selling information / materials prepared and ready for distribution (Descriptive Memorandum, Data Room, Management Presentation) Required content / form of proposal to qualify a buyer for continued discussions Financing Availability of comparable financing for prospective buyers Ensure presumptive buyer has not locked up financing sources Ensure diligence information is ready / appropriate for financing sources Ensure internal approval process of financing sources is factored into time negotiated to solicit proposals Voting / Support Agreements Terms under which a large shareholder will support an alternative proposal Management Support Availability of management to participate in alternative transaction Scope of Allowed Transactions Whether to allow parts of business to be sold separately Tax considerations crucial Break-up Fee Absolute amount of fee relative to size of transaction during go-shop period Right to Match Structuring Right-to-Match to ensure prospective buyers believe competition will be fair Critical Factors in Structuring an Effective Go-Shop Process Considerations Factors 37

Go-shop provision offers an alternative to a pre-signing market check Go-Shop Provisions in Merger Agreements Go-shop is an exception to the no-shop, which allows the seller to actively seek, discuss and negotiate an alternative transaction with a third party for a specified period of time (go-shop window) after the merger agreement is signed Used in situations where the board did not have an opportunity to conduct an auction or a market check before signing the agreement Break-up fees in the go-shop window may be lower than break-up fees in subsequent no-shop periods Contractual terms vary around an acquirors' rights during a go-shop period Level of disclosure regarding discussions with other parties Whether target has any duty to negotiate with acquiror if an alternative proposal is received A more common exception to the no-shop is a Window-Shop provision Allows the seller to discuss and negotiate unsolicited offers under certain circumstances Go-Shop Provisions No-shop provision is a covenant in merger agreement that restricts the seller from the following activities with other potential acquirors after the merger agreement is signed: Soliciting alternative transactions Furnishing or providing information Initiation or encouraging discussions Continuing ongoing discussions Waiving outstanding standstill agreements Typically accompanied with a "fiduciary out" to allow activities that are deemed to be required by board's fiduciary duties No-Shop Provisions Go-Shop Provisions Since Beginning of 2007 (1) Deals Go-Shop Provisions 71 No-Shop Provisions 495 Item C 35 Item D 35 Item E 35 Item F 35 # of Go-Shops Deals Sponsors 60 Strategic 11 Item C 35 Item D 35 Item E 35 Item F 35 # of Strategic Go-Shops Deals <= 30 Days 26 31 - 40 Days 18 41 - 45 Days 15 46 - 60 Days 12 Item F 35 Length of Go-Shop Window ___________________________ Source: MergerMetrics. Data based on U.S. targets above $100 million from 1/1/2007 - 10/13/2010, and cash only offers. Median = 40 days 38

Comparable Companies

Comparable Company Analysis Trading Metrics __________________________ Source: FactSet, Company filings, Wall Street research. Market data as of 10/25/2010. Note: NM denotes negative values. Operating Metrics 39

Disclaimer This document has been prepared by Barclays Capital, the investment banking division of Barclays Bank PLC ("Barclays"), for information purposes only. This document is an indicative summary of the terms and conditions of the securities/transaction described herein and may be amended, superseded or replaced by subsequent summaries. The final terms and conditions of the securities/transaction will be set out in full in the applicable offering document(s) or binding transaction document(s). This document shall not constitute an underwriting commitment, an offer of financing, an offer to sell, or the solicitation of an offer to buy any securities described herein, which shall be subject to Barclays' internal approvals. No transaction or services related thereto is contemplated without Barclays' subsequent formal agreement. Barclays is not acting as a fiduciary. Accordingly you must independently determine, with your own advisors, the appropriateness for you of the securities/transaction before investing or transacting. Barclays accepts no liability whatsoever for any consequential losses arising from the use of this document or reliance on the information contained herein. Barclays does not guarantee the accuracy or completeness of information which is contained in this document and which is stated to have been obtained from or is based upon trade and statistical services or other third party sources. Any data on past performance, modelling or back-testing contained herein is no indication as to future performance. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any modelling or back-testing or any other information contained herein. All opinions and estimates are given as of the date hereof and are subject to change and Barclays assumes no obligation to update this document to reflect any such changes. The value of any investment may fluctuate as a result of market changes. The information herein is not intended to predict actual results and no assurances are given with respect thereto. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice. Barclays, its affiliates and the individuals associated therewith may (in various capacities) have positions or deal in transactions or securities (or related derivatives) identical or similar to those described herein. IRS Circular 230 Disclosure: Barclays Capital and its affiliates do not provide tax advice. Please note that (i) any discussion of U.S. tax matters contained in this communication (including any attachments) cannot be used by you for the purpose of avoiding tax penalties; (ii) this communication was written to support the promotion or marketing of the matters addressed herein; and (iii) you should seek advice based on your particular circumstances from an independent tax advisor. BARCLAYS CAPITAL INC., THE UNITED STATES AFFILIATE OF BARCLAYS CAPITAL, THE INVESTMENT BANKING DIVISION OF BARCLAYS BANK PLC, ACCEPTS RESPONSIBILITY FOR THE DISTRIBUTION OF THIS DOCUMENT IN THE UNITED STATES. ANY TRANSACTIONS BY U.S. PERSONS IN ANY SECURITY DISCUSSED HEREIN MUST ONLY BE CARRIED OUT THROUGH BARCLAYS CAPITAL INC., 200 PARK AVENUE, NEW YORK, NY 10166. NO ACTION HAS BEEN MADE OR WILL BE TAKEN THAT WOULD PERMIT A PUBLIC OFFERING OF THE SECURITIES DESCRIBED HEREIN IN ANY JURISDICTION IN WHICH ACTION FOR THAT PURPOSE IS REQUIRED. NO OFFERS, SALES, RESALES OR DELIVERY OF THE SECURITIES DESCRIBED HEREIN OR DISTRIBUTION OF ANY OFFERING MATERIAL RELATING TO SUCH SECURITIES MAY BE MADE IN OR FROM ANY JURISDICTION EXCEPT IN CIRCUMSTANCES WHICH WILL RESULT IN COMPLIANCE WITH ANY APPLICABLE LAWS AND REGULATIONS AND WHICH WILL NOT IMPOSE ANY OBLIGATION ON BARCLAYS OR ANY OF ITS AFFILIATES. THIS DOCUMENT DOES NOT DISCLOSE ALL THE RISKS AND OTHER SIGNIFICANT ISSUES RELATED TO AN INVESTMENT IN THE SECURITIES/TRANSACTION. PRIOR TO TRANSACTING, POTENTIAL INVESTORS SHOULD ENSURE THAT THEY FULLY UNDERSTAND THE TERMS OF THE SECURITIES/TRANSACTION AND ANY APPLICABLE RISKS. Barclays Bank PLC is registered in England No. 1026167. Registered Office: 1 Churchill Place, London E14 5HP. Copyright Barclays Bank PLC, 2010 (all rights reserved). This document is confidential, and no part of it may be reproduced, distributed or transmitted without the prior written permission of Barclays. 40